Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.
Kliem
V
V
Abteilung Nephrologie, Medizinische Hochschule Hannover, Germany.
Radermacher
J
J
Hiss
M
M
Pethig
M
M
Burg
M
M
Brunkhorst
R
R
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000401:mortality; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D016559:Tacrolimus; D008775:Methylprednisolone